NASDAQ · CRVO

CervoMed Inc.

$2.66 -$0.01 (-0.37%) 1D After hours

Key Metrics

$24.72M
Market cap
P/E · TTM
$2.09M
Revenue · TTM
−$30.04M
Net income
EPS · TTM $-3.45
Dividend yield
Free cash flow
Beta · 1Y 1.93
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 16
    The stock moved +82.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 16
  • Jun 10
    From its Feb 9 high, the share price fell 59%.

    Peak close $5.50 on Feb 9; trough close $2.25 on Jun 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -59%
  • Jun 10
    The stock moved -22.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 10

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$24.72M
Enterprise value
Shares outstanding9.3M
52-wk range$2.13 – $13.13
Avg volume · 20D986.4K
Net cash
Book value / share$1.22
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About CervoMed Inc.
IPO dateJun 18, 1996
Employees15

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S11.83
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -1,488.9%
Net -1,437.8%
FCF
ROE / ROIC -120.6% · —

Financial Health

Current ratio
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital

Cash Flow · TTM

Operating CF −$27.57M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-13.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings